Aug 31, 2021

Featuring slide presentations and related discussion from Drs Petros Grivas, Daniel P Petrylak and Arlene Siefker-Radtke, including the following topics:

• Key Data Supporting the Use of Antibody-Drug Conjugates in Bladder Cancer — Daniel P Petrylak, MD (0:00)
• Approved and Investigational FGFR-Targeted Therapies...

Aug 31, 2021

Featuring perspectives from Drs Petros Grivas, Daniel P Petrylak and Arlene Siefker-Radtke, including the following topics:

• Introduction (0:00)
• Treatment of Metastatic Urothelial Bladder Cancer (mUBC) — Third Line and Beyond (9:03)
• Non-Muscle-Invasive Bladder Cancer; First- and Second-Line Therapy for mUBC (50:35)

Aug 30, 2021

Featuring slide presentations and related discussion from Prof Johann de Bono and Drs Emmanuel S Antonarakis and Julie N Graff, including the following topics:

• Integration of PARP Inhibitors into the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) — Johann de Bono, MBChB, MSc, PhD...

Aug 30, 2021

Featuring perspectives from Prof Johann de Bono and Drs Emmanuel S Antonarakis and Julie N Graff, including the following topics:

• Introduction (0:00)
• Integration of PARP Inhibitors into the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) (3:32)
• Selection and Sequencing of Therapy in mCRPC...

Aug 28, 2021

Featuring perspectives from Dr Noopur Raje and Ms Alli McClanahan, including the following topics:

• Introduction (0:00)
• Case: A man in his mid-50s with IgA kappa MM — Noopur Raje, MD (12:32)
• Case: A man in his mid-60s with IgA kappa MM — Alli McClanahan, MSN, APRN, ANP-BC (34:17)
• Case: A woman in her late 70s with...